Nestle Pairs Nutrition Science Business With Pharma Firm Making Peanut Allergy Treatment
Nestle agrees to acquire Aimmune Therapeutics, maker of a drug indicated to reduce the severity of children’s allergic reactions to peanuts. It anticipates options to innovate in its consumer health children’s allergy business.
You may also be interested in...
Cefaly touts first OTC dual-Purpose eTNS migraine device available in US; Nestle Health Science closes on its acquisition of Aimmune Therapeutics; Elderberry supplement marketer Matherson Organics complies with NAD recommendations rather than face FTC scrutiny; and nutrition product firm Vidafuel closes on $1.6m financing round.
Nestle Health Science acquires IM HealthScience, marketer of medical foods IBgard and FDgard as well as prebiotic and sleep aid supplements. The deal is second recent US consumer health addition for the firm after it said 2020 would be “‘more vigorous” year for acquisitions despite the COVID-19 pandemic.
The French company's hopes of joining Aimmune's Palforzia on the peanut allergy market soon have been shattered after US regulators issued a complete response letter to its Viaskin Peanut patch. A lot now depends on how much work DBV will have to do to satisfy the FDA.